Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 10Paclitaxel 8Bevacizumab 7Cyclophosphamide 6olaparib 5niraparib 5Fulvestrant 4talazoparib 3Radiotherapy 3Gemcitabine 3Capecitabine 3veliparib 2palbociclib 2eribulin 2dostarlimab 2aldesleukin 2Trastuzumab 2Specimen Handling 2Letrozole 2Drug Therapy 2Doxorubicin 2Cisplatin 2Celecoxib 2Biopsy 2Albumin-Bound Paclitaxel 2tucotuzumab celmoleukin 1trastuzumab duocarmazine 1trastuzumab biosimilar HLX02 1sotigalimab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ovarian Neoplasms × Selenium × Clear all
NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

City of Hope Medical Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡